Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.89 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrrolidine SCHEMBL2561 | 1.00 | — | — | |
| Pyrrolidine SCHEMBL7827746 | 1.00 | ALDH1A1 (0.89) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Pyrrolidine SCHEMBL622433 | 1.00 | — | — | |
| Pyrrolidine SCHEMBL148449 | 1.00 | — | — | |
| Pyrrolidine SCHEMBL11288790 | 1.00 | — | — | |
| Pyrrolidine SCHEMBL11536210 | 1.00 | — | — | |
| Pyrrolidine SCHEMBL27811068 | 1.00 | — | — | |
| SCHEMBL3811182 | 1.00 | ALDH1A1 (0.89) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| SCHEMBL576640 | 1.00 | ALDH1A1 (0.89) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Azepane SCHEMBL11361504 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013221-B1 | COMPOSITIONS AND METHODS FOR CELLULAR IMAGING AND THERAPY | UNIV TEXAS (US) | 2015-06-24 | — | — | EP | disclosed |
| EP-2013221-B1 | COMPOSITIONS AND METHODS FOR CELLULAR IMAGING AND THERAPY | UNIV TEXAS (US) | 2015-06-24 | — | — | EP | disclosed |
| US-8758723-B2 | Compositions and methods for cellular imaging and therapy | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-06-24 | — | — | US | disclosed |
| US-8758723-B2 | Compositions and methods for cellular imaging and therapy | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-06-24 | — | — | US | disclosed |
| US-8758723-B2 | Compositions and methods for cellular imaging and therapy | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-06-24 | — | — | US | disclosed |
| US-20100104511-A1 | METHODS AND COMPOSITIONS USING CHELATOR-ANTIBODY CONJUGATES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100104511-A1 | METHODS AND COMPOSITIONS USING CHELATOR-ANTIBODY CONJUGATES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-04-29 | — | — | US | disclosed |
| EP-2146632-A1 | COMPOSITIONS AND METHODS FOR CELLULAR IMAGING AND THERAPY | The Board of Regents of The University of Texas System (US) | 2010-01-27 | — | — | EP | disclosed |
| EP-2013221-A1 | COMPOSITIONS AND METHODS FOR CELLULAR IMAGING AND THERAPY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008130439-A1 | COMPOSITIONS AND METHODS FOR CELLULAR IMAGING AND THERAPY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130439-A1 | COMPOSITIONS AND METHODS FOR CELLULAR IMAGING AND THERAPY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2007120153-A1 | COMPOSITIONS AND METHODS FOR CELLULAR IMAGING AND THERAPY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070248537-A1 | Compositions and Methods for Cellular Imaging and Therapy | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2007-10-25 | — | — | US | disclosed |
| US-20070248537-A1 | Compositions and Methods for Cellular Imaging and Therapy | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2007-10-25 | — | — | US | disclosed |
| US-20070248537-A1 | Compositions and Methods for Cellular Imaging and Therapy | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104511-A1 | METHODS AND COMPOSITIONS USING CHELATOR-ANTIBODY CONJUGATES | ERBB2, EGFR, ERBB3 | ALDH1A1 4692/4885CXCR4 2571/4885SMN1; SMN2 3640/4885 |
| US-20070248537-A1 | Compositions and Methods for Cellular Imaging and Therapy | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCL, NME4 | ALDH1A1 4432/4885CXCR4 45/4885SMN1; SMN2 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.